All News

Moderate physical activity may improve progression-free survival and reduce treatment-related adverse effects in patients undergoing chemotherapy for advanced colorectal cancer.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Combination of ibrutinib and rituximab found to improve overall survival in patients with chronic lymphocytic leukemia.

Zanubrutinib, a Bruton’s tyrosine kinase inhibitor, is being evaluated in a broad pivotal clinical program across multiple B-cell malignancies.

Top news of the day from across the health care landscape.

A recent study demonstrates the clinical benefit from the use of direct-acting antivirals for hepatitis C virus in patients with a history of liver cancer.

Top news of the day from across the health care landscape.

Novel process may identify cancer metastasis at an earlier stage when it may be easier to treat.

Despite e-commerce disruptions to the industry, a recent study found that the United States pharmacy industry continues to maintain high levels of customer satisfaction in both the brick-and-mortar and mail order segments.

Erin Fox, PharmD, BCPS, FASHP will be presenting the American Society of Health-System Pharmacists (ASHP) tenth annual William A. Zellmer Lecture on September 10, 2019, as recipient of the 2019 Zellmer Lecture Award.

Videos, podcasts, articles, and apps are readily available at our fingertips (literally) to help pharmacy students comprehend difficult subjects.

Cancers of the lung, breast, prostate, and colon are most common in adults aged 85 years and older.

Research highlights the importance of regular blood testing to impove earlier detection of multiple myeloma.

Top news of the day from across the health care landscape.

In recent months, legislation to increase access to pre- and post-exposure prophylaxis (PrEP and PEP) passed in California with a vote of 34-1 in the Senate and a unanimous vote in the Assembly.

A phase 3 study evaluated the safety and efficacy of oral paclitaxel versus intravenous paclitaxel monotherapy in patients with metastatic breast cancer.

What is causing this person to cough up blood after he quit smoking cigarettes and a tobacco pipe?

Aspirin therapy found to improve liver function test results and survival after transarterial embolization for hepatocellular carcinoma.

Top news of the day from across the health care landscape.

Officials with the FDA have approved AbbVie’s upadacitinib (Rinvoq) 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR).

Study recommends similar clinical thresholds for diagnosing and managing giant cell arteritis for patients of different ethnicities.

Upadacitinib (Rinvoq, AbbVie) is indicated for adults with moderate-to-severe rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

A phase 4 head-to-head trial compared ixekizumab (Taltz) with guselkumab (Tremfya) in patients with moderate-to-severe plaque psoriasis.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

The approval of fedratinib (Inrebic, Celgene) provides another treatment option for patients with myelofibrosis, a rare bone marrow disorder.

Officials with the FDA have granted approval to entrectinib (Rozlytrek, Genentech) for 2 different cancer indications.